Alere NT-proBNP for Alinity i
Axis-Shield Diagnostics, Ltd. · Decision date Feb 18, 2026
What did the FDA decide?
FDA records K253539 as a 510(k) premarket notification, with a decision dated Feb 18, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Feb 18, 2026
Regulatory record facts
- Identifier
- K253539
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Axis-Shield Diagnostics, Ltd.
- Product code
- NBC
- Decision code
- SESE
- Decision date
- Feb 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Natriuretic Peptide.
- Applicant
- Axis-Shield Diagnostics, Ltd.
- Product code
- NBC
- FDA device class
- 2
FDA decision timeline
K253539 received
Application receipt date recorded by FDA.
K253539 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Access BNP IIK262597 | BECKMAN COULTER, INC. | 510(k) clearance | Oct 20, 2026 | FDA |
Access NT-proBNPK262109 | BECKMAN COULTER, INC. | 510(k) clearance | Sep 21, 2026 | FDA |
Access BNP IIK252169 | BECKMAN COULTER, INC. | 510(k) clearance | Mar 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Axis-Shield Diagnostics, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Dundee
Sources and methodology
- Original FDA record: K253539
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
